PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
289 / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-0.00%
Negative revenue growth while ECL.AX stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-0.00%
Negative gross profit growth while ECL.AX is at 0.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
0.00%
EBIT growth of 0.00% while ECL.AX is zero. Bruce Berkowitz would see if small gains can be scaled further.
0.00%
Operating income growth of 0.00% while ECL.AX is zero. Bruce Berkowitz would see if this modest edge can become significant.
0.00%
Net income growth of 0.00% while ECL.AX is zero. Bruce Berkowitz would see if small gains can accelerate into a larger gap.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.33%
Share change of 0.33% while ECL.AX is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-84.63%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-69.45%
Negative 5Y CAGR while ECL.AX stands at 15.21%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-57.15%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
No Data
No Data available this quarter, please select a different quarter.
-115.67%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-37.87%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-103.43%
Negative 10Y net income/share CAGR while ECL.AX is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-130.23%
Negative 5Y net income/share CAGR while ECL.AX is 415.39%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
63.17%
Positive short-term CAGR while ECL.AX is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.33%
We have a declining book value while ECL.AX shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
463.46%
R&D growth of 463.46% while ECL.AX is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
-0.00%
We cut SG&A while ECL.AX invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.